Cargando…
Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
Multiple Myeloma (MM), the second most common hematologic malignancy, has been the target of many therapeutic advances over the past two decades. The introduction of novel agents, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, along with autologous hematopoietic st...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825476/ https://www.ncbi.nlm.nih.gov/pubmed/35155198 http://dx.doi.org/10.3389/fonc.2021.801851 |